The estimated Net Worth of Alfred J Novak is at least $1.88 Миллион dollars as of 15 June 2022. Mr. Novak owns over 1,346 units of LivaNova PLC stock worth over $603,279 and over the last 9 years he sold LIVN stock worth over $1,030,218. In addition, he makes $242,890 as Independent Director at LivaNova PLC.
Sign up
Mr. Novak LIVN stock SEC Form 4 insiders trading
Alfred has made over 17 trades of the LivaNova PLC stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 1,346 units of LIVN stock worth $63,868 on 15 June 2022.
The largest trade he's ever made was selling 4,000 units of LivaNova PLC stock on 6 May 2016 worth over $204,480. On average, Alfred trades about 1,095 units every 86 days since 2016. As of 15 June 2022 he still owns at least 12,714 units of LivaNova PLC stock.
You can see the complete history of Mr. Novak stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Alfred Novak biography
Alfred J. Novak is Independent Director of the Company. Prior to that, Mr. Novak served as President and CEO of Syntheon Cardiology LLC, an early-stage company developing a percutaneous prosthetic aortic heart valve (2014 to 2015); Chairman and CEO of OrbusNeich Medical Technology Company, Ltd., an interventional cardiology company (2010 to 2013); President and CEO of Novoste Corporation, an interventional cardiology company (2002 to 2006); founder of Syntheon, LLC, a company focused on minimally invasive medical devices for the gastroenterology and vascular markets (1998 to 2003); and President, CEO and a director of Biosense, Inc., an electrophysiology company (1996 to 1998). Prior to that time, Mr. Novak was Vice President and Chief Financial Officer of Cordis Corporation. Mr. Novak received a BS from the United States Merchant Marine Academy and an M.B.A. in Healthcare from The Wharton School of the University of Pennsylvania.
What is the salary of Alfred Novak?
As the Independent Director of LivaNova PLC, the total compensation of Alfred Novak at LivaNova PLC is $242,890. There are 9 executives at LivaNova PLC getting paid more, with Damien McDonald having the highest compensation of $7,131,930.
How old is Alfred Novak?
Alfred Novak is 72, he's been the Independent Director of LivaNova PLC since 2015. There are 2 older and 19 younger executives at LivaNova PLC. The oldest executive at LivaNova PLC is Arthur Rosenthal, 73, who is the Independent Director.
What's Alfred Novak's mailing address?
Alfred's mailing address filed with the SEC is 20 EASTBOURNE TERRACE, , LONDON, X0, W2 6LG.
Insiders trading at LivaNova PLC
Over the last 9 years, insiders at LivaNova PLC have traded over $79,802,010 worth of LivaNova PLC stock and bought 4,000 units worth $268,530 . The most active insiders traders include William A Kozy, Two S.C.A.Tower 6 S. A R.L.... и Peter M Wilver. On average, LivaNova PLC executives and independent directors trade stock every 10 days with the average trade being worth of $315,922. The most recent stock trade was executed by Peter M Wilver on 15 June 2024, trading 2,680 units of LIVN stock currently worth $127,166.
What does LivaNova PLC do?
livanova plc is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. our advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems.at livanova, we understand the importance of bringing both clinical and economic value to our customers. we are a strong, market-leading medical technology and services company, offering a diverse product portfolio and global reach. livanova is listed on the nasdaq stock exchange under the ticker symbol “livn.” livanova has approximately 3,000 employees worldwide. we are headquartered in london (uk) and maintain a presence in more than 100 countries. livanova is a worldwide leader in advanced circulatory support, cardiopulmonary and neuromodulation, dedicated to creating meaningful products and therapies that transform lives each and every day.
What does LivaNova PLC's logo look like?
Complete history of Mr. Novak stock trades at LivaNova PLC
LivaNova PLC executives and stock owners
LivaNova PLC executives and other stock owners filed with the SEC include:
-
Damien McDonald,
Chief Executive Officer, Director -
Keyna Skeffington,
Senior Vice President, General Counsel and Company Secretary -
Alistair Simpson,
Special Advisor -
Edward Andrle,
Special Advisor -
Damien McDonald,
CEO & Director -
Keyna Pidcock Skeffington,
Sr. VP, Gen. Counsel & Corp. Sec. -
Alex Shvartsburg,
CFO and Corp. VP of Financial Planning, Analysis & International Region -
Daniel Moore,
Independent Chairman of the Board -
Hugh Morrison,
Independent Director -
Alfred Novak,
Independent Director -
Francesco Bianchi,
Independent Director -
Arthur Rosenthal,
Independent Director -
Andrea Saia,
Independent Director -
Sharon O'Kane,
Independent Director -
William Kozy,
Independent Director -
Stacy Seng,
Independent Director -
Marco Dolci,
Head of Global Operations and R&D -
Roy Khoury,
President - International, Senior Vice President - Global Strategic Marketing -
Trui Hebbelinck,
Chief Human Resource Officer -
Alex Shvartsburg,
Interim Chief Financial Officer -
Stephanie Bolton,
Pres of International Region -
Paul R. Buckman,
Pres of Advanced Circulatory Support & GM of Transcatheter Mitral Valve Replacement -
Dr. Bryan D. Olin Ph.D.,
Sr. VP & Head of Product Devel. - Neuromodulation -
Trui Hebbelinck,
Chief HR Officer -
Matthew Joseph Dodds III,
Sr. VP of Corp. Devel. -
Deanna Wilke,
Director of Corp. Communications -
Lullo Stefano Di,
Pres Cardiac Rhythm Mgmt -
Michel Darnaud,
President Cardiac Surgery -
Thad Allen Huston,
Chief Financial Officer -
Vivid Sehgal,
CFO -
Two S.C.A.Tower 6 S. A R.L....,
-
Jacques Gutedel,
President Intercontinental -
Stefano Gianotti,
Director -
Piero Vecchi,
VP & Controller -
Pritpal Shinmar,
SR VP Global Market Access -
Robert Jason Richey,
President, Neuromodulation -
Douglas John Manko,
Chief Accounting Officer -
David S Wise,
SR VP HR & IT -
Todd C Schermerhorn,
Director -
Ahmet Tezel,
Chief Innovation Officer -
Brian Sheridan,
SR VP Genl Counsel & Secretary -
Andre Michel Ballester,
CEO -
Demetrio Mauro,
Chief Integration Officer -
James Christopher Barry,
Director -
Peter M Wilver,
Director -
Brooke Story,
Director -
Michael Damon Hutchinson,
Chief Legal Officer -
Stephanie Bolton,
President, Global Epilepsy -
Vladimir Makatsaria,
Chief Executive Officer